Core Viewpoint - The company YiFan Pharmaceutical is engaged in ongoing discussions regarding its research project F-652, particularly in relation to its collaboration with a funding agency for further clinical development in the U.S. [1] Group 1: Company Developments - YiFan Pharmaceutical received a question from an investor about the recent licensing agreement between Hengrui and GSK, which included an upfront payment of $500 million and potential future payments totaling up to $12 billion [1] - The company confirmed that the research project F-652, targeting alcoholic liver disease, will prioritize collaboration with the funding agency for subsequent research in the U.S. [1] - The decision on further discussions regarding business development (BD) will be made after obtaining relevant clinical data [1]